News Center

News Center

News Center

FDA Clearance of Investigational New Drug Application Received for Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418

Phase 1/2 first-in-human clinical study planned this year

2024-11-04

DualityBio's First-in-Class ADC Drug DB-2304 for Autoimmune Diseases Completes First Global Patient Dosing in Phase I Clinical Trial
2024-09-09

DualityBio's Next-Generation Bispecific ADC DB-1419 Receives FDA IND Approval and Completes First Global Patient Dosing

«
1
2
3
»

Scan the code to follow DualityBio official wechat

Phone：021-2601 8730

Address：Full floor, 11th floor, tower a, Datang International Plaza,China

Construction Engineering Group, No. 868 Yinghua Road, Pudong New Area, Shanghai